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http://dx.doi.org/10.1016/j.stemcr.2017.06.007SUMMARYConnexin43 (CX43), a protein that formsgap junction channels andhemichannels in astrocytes, is downregulated inhigh-grade gliomas.
Its relevance for glioma therapy has been thoroughly explored; however, its positive effects on proliferation are counterbalanced by its
effects onmigrationand invasion.Here,we showthat a cell-penetratingpeptide basedonCX43 (TAT-Cx43266-283) inhibited c-Src and focal
adhesionkinase (FAK) andupregulatedphosphatase and tensinhomolog ingliomastemcells (GSCs) derived frompatients.Consequently,
TAT-Cx43266-283 reducedGSCmotility, as analyzed by time-lapsemicroscopy, and strongly reduced their invasive ability. Interestingly, we
investigated the effects of TAT-Cx43266-283 on freshly removed surgical specimens as undissociated glioblastoma blocks, which revealed a
dramatic reduction in the growth, migration, and survival of these cells. In conclusion, a region of CX43 (amino acids 266–283) exerts an
important anti-tumor effect in patient-derived glioblastoma models that includes impairment of GSC migration and invasion.INTRODUCTION
Connexin43 (CX43) is an integral membrane protein that
is widely expressed in astrocytes (Giaume et al., 2010) and
is downregulated in high-grade gliomas, themost common
malignant tumor of the CNS (Crespin et al., 2016; Huang
et al., 1999; Pu et al., 2004; Shinoura et al., 1996; Soroceanu
et al., 2001). Patients diagnosed with glioblastoma multi-
forme, the most aggressive form of glioma, have a median
survival rate of 1–2 years (Gilbert et al., 2014) because of the
infiltrative nature of these tumors, which facilitates recur-
rence after surgery and standard therapy. These tumors
are composed of a heterogeneous population of cells,
including many with stem cell-like properties, called gli-
oma-initiating cells or glioma stem cells (GSCs). GSCs are
characterized by their self-renewal capacity, high onco-
genic potential, resistance to standard therapies (Chen
et al., 2012; Dirks, 2010), and high invasive capacity
(Cheng et al., 2011; Garcia et al., 2010).
GSCs express very low levels of CX43.When this protein
is restored, the stem cell phenotype of GSC lines is reversed
and their tumorigenicity is reduced (Gangoso et al., 2014;
Yu et al., 2012). Our previous studies revealed that CX43
exerts this effect through the inhibition of c-Src activity.
Thus, restoring CX43 inhibited the oncogenic activity of
c-Src in different glioma cell lines (Gangoso et al., 2014;
Gonzalez-Sanchez et al., 2016; Herrero-Gonzalez et al.,
2010). Inhibition of c-Src is caused by a short region, resi-
dues 266–283, within the C-terminal domain of CX43Stem Cell
This is an open access article under the Cthat recruits c-Src together with its inhibitors, C-terminal
Src kinase (CSK) and phosphatase and tensin homolog
(PTEN) (Gonzalez-Sanchez et al., 2016). In fact, cell-pene-
trating peptides containing the CX43 residues 266–283
(TAT-Cx43266-283) are able to mimic these effects. Indeed,
as a result of c-Src inhibition, TAT-Cx43266-283 increased
PTEN, with subsequent inactivation of AKT (Gonzalez-
Sanchez et al., 2016), downregulated the expression of
the inhibitor of differentiation (ID1), and the transcription
factor, SOX-2, and promoted cadherin switching (Gangoso
et al., 2014) in the GSC lines GliNS2 and G166. Conse-
quently, the ability of GlinNS2 and G166 GSCs to prolifer-
ate and generate neurospheres decreased and the percent-
age of cells expressing differentiation markers increased
in the presence of TAT-Cx43266-283 (Gangoso et al., 2014;
Gonzalez-Sanchez et al., 2016).
One important substrate of c-Src is focal adhesion kinase
(FAK). c-Src binds to FAK and phosphorylates the tyrosine
residues 576 and 577 in the activation loop of FAK (Calalb
et al., 1995), thereby maximizing its kinase activity and
creating additional protein binding sites (Mitra and
Schlaepfer, 2006). This active FAK-Src complex stimulates
the activity of RAC1 and CDC42 to increase membrane
protrusions and mediates the transient suppression of
RHOA-GTP levels, thereby facilitating cell spreading. Not
surprisingly, both Src–/– and FAK (Ptk2)/ fibroblasts
display impaired migration (Ilic et al., 1995; Klinghoffer
et al., 1999). c-Src and FAK are required for the processes
of cell invasion and migration in tumor cells (CarragherReports j Vol. 9 j 451–463 j August 8, 2017 j ª 2017 The Author(s). 451
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2006; vanNimwegen et al., 2005), including glioblas-
toma (Du et al., 2009; Lindemann et al., 2011) and GSCs
(Frolov et al., 2016; Liu et al., 2016). In fact, the activity
of both c-Src and FAK are augmented in glioblastomas
(Riemenschneider et al., 2005; Zhang et al., 2011). In addi-
tion, PTEN, as a tyrosine phosphatase, interacts directly
with and dephosphorylates FAK (Cai et al., 2005; Tamura
et al., 1998), leading to suppression of glioma cell migra-
tion and invasion (Park et al., 2002).
As previously mentioned, the major obstacle to devel-
oping a cure for glioblastoma is its diffuse invasion prop-
erty, which enables GSCs to escape complete surgical
resection, chemotherapy, and radiation therapy. Therefore,
an important therapeutic aim is to reduceGSCmotility and
invasion. Because TAT-Cx43266-283 inhibits c-Src activity
and upregulates PTEN, in this study, we investigated
whether TAT-Cx43266-283 reduces FAK activity with subse-
quent impairment in GSC motility and invasive capacity.RESULTS
TAT-Cx43266-283 Inhibits c-Src Activity and
Upregulates PTEN in Primary Glioblastoma StemCells
Our previous studies showed that cell-penetrating peptides
containing the residues of CX43 involved in the interac-
tion with c-Src (residues 266–283) fused to the TAT-pene-
trating sequence (TAT-Cx43266-283) inhibit c-Src activity
in the human GSC lines GliNS2 and G166 (Gangoso
et al., 2014; Gonzalez-Sanchez et al., 2016). In this study,
we investigated whether this effect also occurs in GSCs
derived directly frompatients (primaryGSCs). To do so, pri-
mary GSCs were obtained and cultured from human glio-
blastoma biopsies immediately after surgery, as described
previously (Pollard et al., 2009; Thirant et al., 2011). As
expected, most of the cells in these cultures expressed the
stem cell markers SOX-2 and Nestin (Figures 1A and S1).
The c-Src activity was analyzed by measuring the levels of
c-Src phosphorylated at Tyr416 (Y416 c-Src), the active
form of this tyrosine kinase (Kmiecik and Shalloway,
1987). Our results showed that the level of activated c-Src
decreased after 24 hr of incubation with 50 mM TAT-
Cx43266-283 compared with cells incubated with 50 mM
TAT-penetrating peptide (TAT) or with control (Figures 1B
and 1C) in primary GSCs derived from five glioblastoma
patients (G9, G12, G13, G15, and G16). These results indi-
cate that TAT-Cx43266-283 inhibits c-Src activity also in pri-
mary GSCs.
As a result of c-Src inhibition, TAT-Cx43266-283 increases
PTEN, with subsequent AKT inactivation and a reduction
in G166 GSC proliferation and survival (Gonzalez-Sanchez
et al., 2016). Because PTEN is one of the most relevant
tumor suppressor proteins in gliomas (Cancer Genome452 Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017Atlas Research Network, 2008), in this study, we analyzed
the effect of TAT-Cx43266-283 on PTEN in primary GSCs.
Our data revealed that TAT-Cx43266-283 upregulated the
PTEN levels in these primary GSCs (Figures 1B and 1D).
TAT-Cx43266-283 Targets FAK
FAK autophosphorylation at Tyr397 (Y397 FAK) creates a
binding site for c-Src that phosphorylates FAK at Tyr576
(Y576 FAK) and Tyr577 (Y577 FAK), promoting maximal
FAK catalytic activity. In fact, FAK phosphorylation at
Y576 and Y577 is required for maximal Y397 phosphoryla-
tion (Ruest et al., 2000). In addition, PTEN dephosphory-
lates Y397 FAK, which decreases FAK activity (Tamura
et al., 1998). Therefore, in this study, we investigated
whether changes in the c-Src activity and PTEN levels pro-
moted by TAT-Cx43266-283 impact FAK activity in GSCs.
Our results showed that, except for G12 GSCs, in which
changes were not statistically significant, incubation with
50 mM TAT-Cx43266-283 for 24 hr decreased the Y397 FAK
phosphorylation levels compared with incubation with
TAT or control in primary GSCs (Figures 1B and 1E).
We also analyzed the effect of TAT-Cx43266-283 on FAK
residues that were directly phosphorylated by c-Src (Y576
and Y577). Figure 2A shows that primary G9 GSCs incu-
batedwith 25 or 50 mMTAT-Cx43266-283 for 15 hr had lower
levels of Y576 and Y577 FAK compared with those incu-
bated with the same TAT concentrations. In fact, as soon
as 4 hr after 50 mM TAT-Cx43266-283 incubation, the c-Src
activity decreased in primary GSCs, although no changes
in FAK phosphorylation were found (Figure S2). However,
2 hr later, i.e., 6 hr after incubation with 50 mM TAT-
Cx43266-283, both the c-Src activity and FAK phosphoryla-
tion levels decreased compared with the TAT treatment
(Figure S2), suggesting that inhibition of c-Src activity leads
to a reduction in FAK phosphorylation. Similarly, FAK
phosphorylation at Y576 and Y577 was reduced by
TAT-Cx43266-283 in G166 GSCs (Figure 2B), a cell line in
which the anti-tumor effect of TAT-Cx43266-283 has been
shown to be caused by c-Src inhibition (Gonzalez-Sanchez
et al., 2016).
TAT-Cx43266-283 Reduces GSC Motility
FAK plays a key role in both normal and tumor cell migra-
tion downstream of growth factor and integrin receptors
(McLean et al., 2005). Because TAT-Cx43266-283 inhibits
FAK activity (Figures 1B, 1E, and 2), we investigated the ef-
fect of TAT-Cx43266-283 on GSC migration. Primary G9,
G13, G16, or G166 GSCs were exposed to TAT or TAT-
Cx43266-283 for 15 hr, and their movements were followed
by time-lapse microscopy (representative movies are
shown as Movies S1, S2, and S3). These movies show that
50 mM TAT-Cx43266-283 greatly reduced cell motility in
primary G9 GSCs (Movie S3) compared with the
Figure 1. TAT-Cx43266-283 Targets c-Src,
PTEN, and FAK in Primary GSCs
(A) Phase-contrast images (left) and SOX-2
(red) and Nestin (green) immunostaining
(right) of the same field showing that pri-
mary G9 GSCs express these GSC markers.
Scale bar, 50 mm.
(B) Primary G9, G12, G13, G15, and G16
GSCs were incubated with 50 mM TAT or
50 mM TAT-Cx43266-283. After 24 hr, the
PTEN, total c-Src, Y416 c-Src, total FAK, and
Y397 FAK levels were analyzed by western
blotting.
(C–E) Quantification of the Y416 c-Src/total
c-Src (C), PTEN/a-actinin (D), and Y379
FAK/total FAK (E) ratios. The results were
normalized with their corresponding con-
trols (assigned a value of 1; dotted line) and
are the means ± SEM of at least three
independent experiments (ANOVA; ***p <
0.001, **p < 0.01, *p < 0.05; TAT-Cx43266-283
versus TAT). See also Figure S1.corresponding concentrations of TAT (Movie S2) or with
the control (Movie S1). To quantify these effects, individual
cell trajectories were tracked. Our results clearly show that
the trajectories described for 12–14 hr by G166 GSCs (Fig-
ure 3A) and primary G9, G13, and G16 GSCs (Figures 3C,
4A, and 4C), were shorter when they were exposed to 25
or 50 mM TAT-Cx43266-283 compared with TAT or control.
Indeed, TAT-Cx43266-283, at concentrations ranging from
25 to 50 mM, caused a significant reduction in the path
length described by both G166 and primary GSCs (Figures
3B, 3D, 4B, and 4D).
To test whether these effects were carried out specifically
by TAT-Cx43266-283, we checked the effect of the 274–291
CX43 sequence fused to TAT (TAT-Cx43274-291). It shouldbe mentioned that the 274–291 CX43 sequence does not
recruit c-Src together with its inhibitors, PTEN and CSK
(Gonzalez-Sanchez et al., 2016), and consequently does
not reduce Src activity with the subsequent reversion of
the GSC phenotype in GliNS2 GSCs (Gangoso et al.,
2014). Our results showed that TAT-Cx43274-291 did not
significantly modify the length of the primary G13 and
G16 GSC trajectories (Figures 4B and 4D). To confirm the
participation of FAK in the mechanism by which TAT-
Cx43266-283 reduced GSC motility, FAK activity was in-
hibited with 5 mM FAK inhibitor 14. Figures 4B and 4D
reveal that G13 and G16 GSC motility was strongly
reduced by the FAK inhibitor compared with the control,
indicating that FAK activity is required for GSC motility.Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017 453
Figure 2. TAT-Cx43266-283 Reduces Y576 and Y577 FAK Phos-
phorylation in GSCs
Primary G9 (A) or G166 (B) GSCs were incubated with TAT or
TAT-Cx43266-283. Western blot analysis for FAK, Y576 FAK, and Y577
FAK. The results were normalized with their corresponding TAT
(assigned a value of 1) and are the means ± SEM of at least four
independent experiments (***p < 0.001, **p < 0.01, *p < 0.05;
TAT-Cx43266-283 versus TAT, t test). See also Figure S2.In fact, the effect of FAK inhibitor 14 plus TAT-Cx43266-283
did not affect or slightly increased this effect compared
with the FAK inhibitor alone (Figures 4B and 4D), suggest-
ing that Src-dependent pathways other than FAK have a
minor contribution to the effect of TAT-Cx43266-283 on
migration.
TAT-Cx43266-283 Reduces GSC Invasion
Because TAT-Cx43266-283 affects c-Src, PTEN, and FAK,
three proteins that share common pathways to promote
tumor cell invasion, we further hypothesized that TAT-
Cx43266-283 could decrease the invasive capacity of GSCs.
To address this point, cultures of primary G9 or G166
GSCs were established in a Matrigel transwell system.454 Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017Matrigel is an assortment of extracellular matrix proteins,
mainly laminin, collagen IV, and enactin, and it is consid-
ered to be a reconstituted basementmembrane preparation
(Hughes et al., 2010). Matrigel occludes transwell mem-
brane pores, blocking non-invasive cells from migrating
through. In contrast, invasive cells can degrade the matrix
andmove through the extracellular layer and adhere to the
bottom of the transwell.
Typical fields obtained from the bottom of transwells
after 15 hr of Matrigel invasion, as shown in Figure 5,
show that the ability of the cells to invade the basement
membrane was significantly compromised in TAT-
Cx43266-283-treated primary G9 and G166 GSCs (Figures
5A and 5B) relative to TAT-treated cells. When quantifying
these results, we observed that TAT-Cx43266-283 decreased
the invasion capacity of the primary G9 and G166 GSCs
by approximately 63%–66% and 34%–37%, respectively,
relative to TAT-treated cells. It should be mentioned that
TAT, even at 100 mM, only slightly (11% in primary G9
GSCs) modified or did not modify the invasive ability of
these cells compared with the control (Figure S3). In addi-
tion, the observed reduction in the number of invading
cells was not due to a decrease in cell proliferation or cyto-
toxicity, because TAT-Cx43266-283 applied at such concen-
trations (up to 50 mM) for 15 hr did not affect or only
slightly affected (9% and 13% in G9 at 25 and 50 mM,
respectively; TAT-Cx43266-283 versus TAT) the viability of
primary G9 and G166 GSCs (Figures S4A and S4B).
TAT-Cx43266-283 Dramatically Reduced Growth,
Migration, and Survival of Glioblastoma Cells from
Freshly Removed Surgical Malignant Glioma
Specimens
To test the effect of TAT-Cx43266-283 on GSCmigration and
invasion, concentrations ranging from 25 to 50 mM for
15 hr were chosen to avoid the effects related to GSC
viability (Figures S4A–S4D). TAT-Cx43266-283 inhibits the
oncogenic activity of c-Src, which in addition to its effect
onmigration is involved in a diverse spectrum of cancer tu-
mor events, including the stem cell phenotype, survival,
differentiation, or proliferation (Zhang et al., 2011). In
fact, Figures S4E and S4F and our previous studies show
that TAT-Cx43266-283 at concentrations ranging from 50
to 100 mM for 72 hr inhibited GSC proliferation (Gonza-
lez-Sanchez et al., 2016) and their stem cell phenotype
(Gangoso et al., 2014).
It has been proposed that the culture of human glioblas-
toma explants provides a flexible and rapid platform for
drug screening in a patient-specific fashion (Bayin et al.,
2016). Therefore, in addition to studying the effect of TAT-
Cx43266-283 on GSC migration and invasion, we investi-
gated its anti-tumor effect on freshly removed surgical spec-
imens as undissociated tumor blocks. Thus, explants from
Figure 3. TAT-Cx43266-283 Reduces GSC
Motility
G166 (A and B) or primary G9 GSCs (C and D)
were incubated with 25 or 50 mM TAT or TAT-
Cx43266-283, and their random movements
were recorded by time-lapse microscopy for
12 hr (representative movies from primary
G9 GSCs are available as Supplemental
Information Movies S1, S2, and S3). Track-
plots showing the trajectories described by
nine representative G166 GSCs (A) or seven
primary G9 GSCs (C). The origin of each cell
trajectory is at the intersection of the x and
y axes. Scale bars, 50 mm. (B and D) The
migration length was extracted from the
track-plots using the total path length
described by each individual cell in at least
six movies from three independent experi-
ments. The line bisecting the plot corre-
sponds to the mean (ANOVA; ***p < 0.001;
TAT-Cx43266-283 versus control,
###p <
0.001; TAT-Cx43266-283 versus TAT). Non-
significant differences were found when
control, 25 mM TAT and 50 mM TAT levels
were compared. The trajectories of cells
that died during the time lapse were not
considered. See also Movies S1, S2, and S3.the same tumors used to obtain GSCs were cultured im-
mediately after surgery, exposed to 100 mM TAT or TAT-
Cx43266-283, and cell behavior wasmonitored by time-lapse
microscopy.Despite thedifferent cellmorphologies and fea-
tures found in each tumor, in the control the cells grew
rapidly and exhibited high motility and proliferation
consistent with the strong aggressiveness of these tumors
(Figures 6A and 6B; Movies S4, S6, and S8 for primary G9,
G13, and G16 GSCs, respectively; all were treated with
100mMTAT).Because theexplantswerecultured inGSCme-
dium, which favors the growth and survival of GSCs, most
of thecells expressedSOX-2andNestin (Figure6C). Interest-
ingly, themovies clearly show that 100 mMTAT-Cx43266-283
reduced cell motility and proliferation and promoted cell
death (Movies S5, S7, and S9 for G9, G13, and G16, respec-tively). Consequently, the change in cell number from the
beginning to the end of the experiment was strongly
reduced in G9, G13, or G16 explants by 100 mM TAT-
Cx43266-283 compared with treatments with 100 mM TAT
or with their corresponding controls (Figures 6A and 6B;
Movies S5, S7, and S9 for G9, G13, and G16, respectively).
It should be mentioned that, over the course of these
experiments, we received two surgical specimens that
were finally diagnosed as neuroblastoma (N6) and oligo-
dendroglioma (O17) instead of glioblastoma. Intriguingly,
100 mMTAT-Cx43266-283 rapidly promoted tumor cell death
in the neuroblastoma and oligodendroglioma explants
(data not shown), as it did in the glioblastoma explants,
suggesting that the anti-tumor effect of TAT-Cx43266-283
is not restricted to glioblastoma.Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017 455
Figure 4. Specificity of the Effect of
TAT-Cx43266-283 on FAK-Dependent GSC
Motility
Primary G13 (A and B) or G16 (C and D) GSCs
were incubated with 50 mM TAT, TAT-
Cx43274-291, TAT-Cx43266-283, 5 mM FAK
inhibitor 14 (FAK inh 14), or 5 mM FAK inh
14 + TAT-Cx43266-283, and their random
movements were recorded by time-lapse
microscopy for 14 hr. Track-plots showing
the trajectories described by at least seven
representative G13 (A) or G16 (C) GSCs for
14 hr. The origin of each cell’s trajectory is
at the intersection of the x and y axes. Scale
bars, 50 mm. The migration length was ex-
tracted from the track-plots using the total
path length described by each individual
cell in at least ten movies from three inde-
pendent experiments. The line bisecting the
plot corresponds to the mean (ANOVA;
***p < 0.001, *p < 0.05; versus control;
+++p < 0.001; versus TAT; ###p < 0.001, ##p <
0.01; versus TAT-Cx43274-291;
@p < 0.05; FAK
inh 14 versus FAK inh 14 + TAT-Cx43266-283;
ns, not significant). Non-significant differ-
ences were found when the control, 50 mM
TAT and 50 mM TAT-Cx43274-291 were com-
pared. The trajectories of cells that died
during the time lapse were not considered.DISCUSSION
Although the relationship between connexin and cancer
was first described 50 years ago, the interest in this protein
for use in the development of cancer therapies is increasing
(Aasen et al., 2016). Our previous studies showed that
restoring CX43 in glioma cells that express negligible levels
of CX43 inhibits the activity of c-Src (Gangoso et al., 2014;
Herrero-Gonzalez et al., 2010; Tabernero et al., 2016). This
effect is caused by the recruitment of c-Src, together with its
inhibitors CSK and PTEN, to a short region of CX43 from
amino acids 266–283 (Gonzalez-Sanchez et al., 2016).
Indeed, a cell-penetrating peptide containing this region,
TAT-Cx43266-283, is able to recruit these proteins and conse-456 Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017quently inhibits c-Src and upregulates PTEN, mimicking
the anti-proliferative effect and reversion of the stem
cell phenotype promoted by CX43 in the GSC lines
GliNS2 and G166 (Gangoso et al., 2014; Gonzalez-Sanchez
et al., 2016). In the present study, we found that TAT-
Cx43266-283 inhibited c-Src activity and upregulated PTEN
also in GSCs derived directly from patients. However, it
should be considered that, although restoring CX43 in gli-
oma cells reduces c-Src oncogenic activity, it can also have
detrimental effects because of the increase in cell invasion
(Naus et al., 2016). Interestingly, this study revealed that,
by inhibiting c-Src and increasing PTEN, TAT-Cx43266-283
reduced FAK activity, with subsequent inhibition in GSC
migration and invasion.
Figure 5. TAT-Cx43266-283 Reduces GSC
Invasion
Primary (A) or G166 (B) GSC invasion was
analyzed using a transwell Matrigel invasion
assay. Cells were incubated with TAT or
TAT-Cx43266-283 and were allowed to invade
for 15 hr. The results are expressed as the
number of invading cells per field ± SEM. At
least five fields per insert in nine inserts
from three independent experiments were
counted. Scale bars, 100 mm (***p < 0.001;
t test). See also Figures S3 and S4.It is well known that CX43 plays a significant role in cell
migration, impacting adhesion (Elias et al., 2007), cytoskel-
etal rearrangements, and invasiveness (reviewed in Naus
et al., 2016). Thus, the C-terminal domain of CX43 inter-
acts with crucial proteins for cell motility, such as ZO-1
(Toyofuku et al., 2001), tubulin (Saidi Brikci-Nigassa et al.,
2012), debrin (Ambrosi et al., 2016), and binding partners
of these proteins, such as F-actin. In addition, CX43 can in-
crease gap junctional communication between tumor and
stromal cells, causing a diffusion of molecules that
contribute to tumor cell invasion or metastasis, such as mi-
croRNAs (Hong et al., 2015) or cGAMP (Chen et al., 2016).
Furthermore, the C-terminal domain of CX43 can regulate
signaling molecules that are involved inmigration, such as
p38MAPK (Behrens et al., 2010) or c-Src (Herrero-Gonzalez
et al., 2010). Therefore, it is not surprising that the resultingeffect of CX43 onmigration and invasion varies depending
on the cellular context (Naus et al., 2016), such as the tu-
mor microenvironment or level of activity of the partners
of CX43. For instance, in glioma cells, some studies show
that CX43 increases invasiveness (Lin et al., 2002; Oliveira
et al., 2005; Osswald et al., 2015; Strale et al., 2012). How-
ever, others show the opposite effect: that downregulation
of CX43 promotes glioma migration (Aftab et al., 2015).
To avoid this multifactorial effect, we used a short region
of CX43 (from amino acids 266–283). This region lacks
cytoskeleton-binding motifs and is not able to form gap
junction channels; however, it retains its ability to inhibit
c-Src activity (Gangoso et al., 2014; Gonzalez-Sanchez
et al., 2016). As mentioned in the Introduction, c-Src is a
key regulator of glioma cell migration and invasion because
it phosphorylates and activates FAK (Calalb et al., 1995) andStem Cell Reports j Vol. 9 j 451–463 j August 8, 2017 457
Figure 6. TAT-Cx43266-283ReducesGrowth,
Migration, and Survival in Patient-Derived
Glioblastoma Explants
G9, G13, and G16 glioma explants were
cultured in GSCmedium and incubated in the
absence (control) or presence of 100 mM TAT
or TAT-Cx43266-283 for the indicated times.
(A) Phase-contrast images of the same field
showing cells growing and spreading from
G9, G13, or G16 glioblastoma explants at the
beginning and at the end of the experiment.
Scale bars, 50 mm. Cells were recorded by
time-lapse microscopy. The blocks indicate
the location of the glioblastoma explants.
The full movies are available as Supple-
mental Information Movies S4, S5, S6, S7,
S8, and S9, showing the reduction in the cell
growth, migration, and survival of the ex-
plants treated with TAT-Cx43266-283.
(B) Change in cell number per field from the
beginning to the end of the experiment
expressed as percentage of the cells found at
the beginning of the experiment. The results
are the means ± SEM of three to six fields
in explants from G9, G13, or G16 tumors
(ANOVA; ***p < 0.001, **p < 0.01; TAT-
Cx43266-283 versus control;
###p < 0.001, ##p <
0.01, #p < 0.05; TAT-Cx43266-283 versus TAT).
(C) SOX-2 (red), Nestin (green) immuno-
staining, and merged images of the same
field showing a representative explant
from the G13 tumor. Scale bars, 500 mm. A
magnified inset showing that most cells ex-
press these GSC markers. Scale bar, 50 mm.
See also Movies S4, S5, S6, S7, S8, and S9.promotes degradation of the tumor suppressor protein
PTEN (Lu et al., 2003), whose phosphatase activity inhibits
FAK (Cai et al., 2005; Tamura et al., 1998) (Figure 7A).
Indeed, our results show that TAT-Cx43266-283 inhibits c-
Src activity and upregulates PTEN, with a subsequent
decrease in FAK activity (Figure 7B). Src, PTEN, and FAK
are crucial to trigger a cascade of events that lead to cell
migration and invasion (Mitra and Schlaepfer, 2006; Ya-
mada and Araki, 2001). Consistent with these studies, our
time-lapse movies revealed that random GSC movement
is reduced by the presence of TAT-Cx43266-283, as judged
by the length of the GSC trajectories. Furthermore, TAT-
Cx43266-283 strongly impaired the ability ofGSCs to degrade
the extracellular matrix (Matrigel) and invade transwells,
consistent with a reduction in their invasive capacity.458 Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017Despite the intertumoral heterogeneity, all malignant
gliomas share one conserved feature, aggressive invasive-
ness (Cuddapah et al., 2014), which is one of the most
important consequences of the oncogenic activity of
c-Src (Lund et al., 2006), specifically in GSCs (Liu et al.,
2016). These cells exhibit a high level of c-Src activity
(Han et al., 2014) and PTEN deficiency (Duan et al.,
2015), which are required to invade the brain parenchyma,
escaping surgery (Cheng et al., 2011; Garcia et al., 2010).
As GSCs are resistant to conventional therapy and are
highly tumorigenic, they are thought to be the main cause
of recurrence after surgery and are consequently respon-
sible for the poor survival of these patients (Chen et al.,
2012; Dirks, 2010). Therefore, the results presented in
this study showing inhibition of primary GSC migration
Figure 7. TAT-Cx43266-283 Targets Src, PTEN, and FAK in GSCs
(A) In GSCs, active c-Src phosphorylates FAK at Y576 and Y577, thus
fully activating FAK. Active c-Src also promotes the degradation of
PTEN, an important inhibitor of FAK. The activated Src-FAK axis,
together with low levels of PTEN are crucial to trigger the cascade of
events leading to cellmigration, invasion, proliferation, and survival.
(B) TAT-Cx43266-283 inhibits c-Src activity together with a strong
upregulation of PTEN expression. As a consequence, there is a
decrease in the phosphorylation of FAK at Y576 and Y577 by the low
levels of active c-Src. In addition, the PTEN upregulation contrib-
utes to FAK inactivation by dephosphorylation. Altogether, these
molecular changes reduce the capacity of the GSCs to migrate,
invade, proliferate, and survive.and invasion promoted by TAT-Cx43266-283 are very prom-
ising for therapeutic development against this incurable
disease.
Notably, TAT-Cx43266-283 targets Src and PTEN,which are
critical nodes in signaling pathways that impact prolifera-
tion, migration, invasion, and survival (Knobbe et al.,
2002; Zhang et al., 2011). Furthermore, PTEN is one of
the most frequent genetic alterations found in glioblas-
tomas (Cancer Genome Atlas Research Network, 2008)
and, although genetic analyses did not show any SRC alter-
ations in glioblastoma, tyrosine kinase phosphorylation as-
says have shown that Src activation is a common event in
glioblastoma (Du et al., 2009). Therefore, it is not unex-
pected that TAT-Cx43266-283 exerted a potent anti-tumor
effect on most of the glioblastoma patient explants
analyzed in this study (Movies S4, S5, S6, S7, S8, and S9).
In fact, these results should be highlighted because of the
accuracy of patient-derived models in the identification
of effective cancer treatments (Bayin et al., 2016; Crystal
et al., 2014).
In conclusion, a region of CX43 (amino acids 266–283),
by targeting c-Src, PTEN, and FAK, exerts a potent anti-
tumor effect in patient-derived glioblastoma cells, which
includes an impairment of GSC migration and invasion.
This study reinforces the relevance of this sequence and
encourages further research for the development of new
therapies against glioblastoma.EXPERIMENTAL PROCEDURES
Ethics Statement
Patients provided written informed consent to participate in the
study, and tumor samples and cell culture brain tumor samples
were obtained following local ethical board approval at the Service
of Neurosurgery in the Hospital Universitario de Salamanca
(Spain). The study was approved by the bioethics committee of
the University of Salamanca and Junta de Castilla y León (Spain).GSC Cultures
G166GSCswere obtained fromBioRep (Milan, Italy) (Pollard et al.,
2009). Primary GSCs were obtained and cultured as described pre-
viously (Thirant et al., 2011). In brief, immediately after surgery,
the tumor samples (G9, G12, G13, G15, and G16, diagnosed as
classic glioblastomas; N6, a neuroblastoma; and O17, an oligoden-
droglioma) were washed and deprived of vessels in PBS. After me-
chanical dissociation, the samples were subjected to enzymatic
dissociation with Accutase (Sigma-Aldrich Quı́mica, Madrid,
Spain) for 15–20 min at 37C. These solutions were then filtered
and centrifuged at 1,000 3 g for 5 min. The G166 and primary
GSCs were cultured in RHB-A medium (Takara Bio, Condalab,
Madrid, Spain) supplemented with 2% B27 (Life Technologies,
Thermo Fisher Scientific, Waltham, USA), 1% N2 supplement
(Life Technologies), 20 ng/mL epidermal growth factor (EGF),
and 20 ng/mL basic fibroblast growth factor (b-FGF) (PeproTech,Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017 459
London, UK) under adherent conditions as described by Pollard
et al. (2009). Culture plates were coated with 10 mg/mL laminin
(Life Technologies) for 2 hr before use. The cells were maintained
at 37C in an atmosphere of 95% air/5% CO2 and with 90%–
95% humidity. The G166 and primary GSCs were grown to conflu-
ency, dissociated using Accutase, and then split. We routinely used
cultures expanded for no more than 15 passages.
Cell Treatments
The synthetic peptides (>85% pure) were obtained fromGenScript
(Piscataway, NJ, USA). YGRKKRRQRRR was used as the TAT
sequence, which is responsible for the cell penetration of the pep-
tides (Gangoso et al., 2014). The TAT-Cx43266-283 sequence was
TAT-AYFNGCSSPTAPLSPMSP and the TAT-Cx43274-291 sequence
was TAT-PTAPLSPMSPGYKLVTG. The peptides were used at
different concentrations (25, 50, or 100 mM) in culture medium at
37C for the indicated time. FAK inhibitor 14 (SML0837) was ob-
tained from Sigma and used at 5 mM.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 20 min. A mouse
monoclonal antibody against human Nestin (1:200; Abcam, Cam-
bridge, UK; Ref. ab18102) was applied overnight at 4C, followed
by incubation with an Alexa Fluor 488-conjugated anti-mouse
immunoglobulin G (IgG) antibody (1:1,000; Life Technologies;
Ref. A-11029) for 2 hr. A rabbit polyclonal antibody against SOX-
2 (1:200; Abcam; Ref. ab97959) was applied overnight at 4C,
followed by incubation with an Alexa Fluor 594-conjugated anti-
rabbit IgG antibody (1:1,000; Life Technologies; Ref. A-11012) for
2 hr. The cells were thenmounted using a SlowFade Light Antifade
Kit (Life Technologies), and they were analyzed on a Leica inverted
fluorescencemicroscope connected to a digital video camera (Leica
DC 100; Leica Microsystems, Wetzlar, Germany).
Migration Assays
G166orprimaryGSCswereplated at a lowdensity (5,000 cells/cm2)
in 24-well plates. Once the cells were attached, TAT or TAT-
Cx43266-283 was added at 25 or 50 mM, and the cells were allowed
to equilibrate for 1–3 hr in the microscope incubator before imag-
ing. Random cell movement was recorded by time-lapse live-cell
imaging for 12–14 hr. The total duration of the treatment was al-
ways 15 hr. Every 10 min, phase-contrast photographs of each
experimental condition were taken with an inverted Zeiss Axio
Observer Z1 microscope for live-cell imaging (Carl Zeiss Micro-
scopy, LLC, USA) coupled to an AxioCam MRm camera. The sys-
tem included an automated XY stage controller and a humidified
incubator set at 37C and 5% CO2. Image stacks were processed,
and cell movement was manually tracked and further analyzed
using Zen imaging software (Carl Zeiss Microscopy). Average cell
length was calculated in at least six independent movies from
three independent experiments.
Glioblastoma Explant Cultures
The tumor samples, immediately after surgery, were washed,
deprived of vessels in PBS and finely minced into approximately
1-mm3 pieces. The explants were plated individually in 24-well
plates and cultured in RHB-A medium (Takara Bio, Condalab,460 Stem Cell Reports j Vol. 9 j 451–463 j August 8, 2017Madrid, Spain) supplemented with 2% B27 (Life Technologies,
Thermo Fisher Scientific, Waltham, USA), 1% N2 supplement
(Life Technologies), 20 ng/mL EGF, and 20 ng/mL b-FGF (Pepro-
Tech, London, UK), as described previously (Bayin et al., 2016).
Culture plates were coated with 10 mg/mL laminin (Life Technolo-
gies) for 2 hr before use. The tumor blocksweremaintained at 37C
in an atmosphere of 95% air/5% CO2 and with 90%–95% humid-
ity. Once the explants were attached (after 24–72 hr), TAT or TAT-
Cx43266-283 was added at 100 mM, and the cells were allowed to
equilibrate for 1–3 hr in the microscope incubator before imaging.
The cells were recorded by time-lapse live-cell imaging for the
indicated times. Every 10 min, phase-contrast photographs of
each experimental condition were taken with an inverted Zeiss
Axio Observer Z1 microscope for live-cell imaging (Carl Zeiss
Microscopy, LLC, USA) coupled to an AxioCam MRm camera.
The system included an automated XY stage controller and a
humidified incubator set at 37C and 5% CO2. Image stacks were
processed using Zen imaging software (Carl Zeiss Microscopy).Invasion Assays
Cell invasionwasmeasured inMatrigel (Corning, Amsterdam, The
Netherlands)-coated transwell inserts (Merck Millipore, Madrid,
Spain) containing polyethylene terephthalate filters with 8-mm
pores. The inserts were coated with 100 mL of 1 mg/mL Matrigel
matrix according to the manufacturer’s recommendations. Next,
7.5 3 104 cells in 200 mL of serum-free medium were plated in
the upper chamber, whereas 500 mL of medium supplemented
with 10% fetal bovine serum (Gibco, Life Technologies) was added
to the lower well. The indicated treatments were added, and the
cells were allowed to invade for 15 hr. Non-invading cells were
carefully removedwithwet cotton swabs from the top of themem-
branes. The invading cells of the lower surface were fixed with 4%
paraformaldehyde for 10 min, washed with PBS, and stained with
Giemsa for 10 min. The inserts were washed with PBS and allowed
to dry. The invading cells were counted in at least five random
fields per insert from three independent experiments. Images
were taken using a Leica microscope connected to a digital camera
(Leica DFC500).Western Blot Analysis
Western blotting was performed as described previously (Herrero-
Gonzalez et al., 2010). In brief, equivalent amounts of proteins
(20 mg per lane) were separated on NuPAGE Novex Bis-Tris (4%–
12%) midi gels (Life Technologies). The proteins were transblotted
using an iBlot dry blotting system (Life Technologies). After
blocking, the membranes were incubated overnight at 4C with
the primary antibodies against Y416 Src (1:200; Cell Signaling,
Danvers, MA, USA; Ref. 2101), total Src (1:500; Cell Signaling;
Ref. 2108), PTEN (1:500; Cell Signaling; Ref. 9556S), Y397 FAK
(1:1,000; Life Technologies; Ref. 44-624G), Y576 FAK (1:500;
Life Technologies; Ref. 44652G), Y577 FAK (1:500; Life Technolo-
gies; Ref. 44-614G), and total FAK (1:500; Life Technologies;
Ref. AHO0502). The antibodies against glyceraldehyde phosphate
dehydrogenase (GAPDH, 1:15,000; Ambion, Thermo Fisher Scien-
tific; Ref. AM4300) or alpha-actinin (1:1,000; Chemicon Interna-
tional, Merck Millipore; Ref. MAB1682) were used as a loading
control. After extensive washing, the membranes were incubated
with peroxidase-conjugated anti-rabbit IgG or the anti-mouse IgG
antibody (Santa Cruz Biotechnology, Dallas, TX, USA; Refs. sc-
2030 and sc-2005) in TTBS and developed with a chemilumines-
cent substrate (Western Blotting Luminol Reagent; Santa Cruz
Biotechnology). X-ray films were obtained from Fujifilm (Madrid,
Spain).
MTTAssay
Cells cultured at 37C in 24-well plates were incubated in the dark
for 75 min with 300 mL of RHB-A medium containing 0.5 mg/mL
MTT (Sigma). The medium was then removed, and the cells were
incubated for 10 min in the dark with DMSO (500 mL per well)
withmild shaking. Finally, the absorbancewasmeasured at awave-
length of 570 nm using a microplate reader (Appliskan 2001;
Thermo Electron Corporation, Thermo Scientific, Madrid, Spain).
Statistical Analysis
The results are expressed as the mean ± SEM of at least three inde-
pendent experiments. Statistical analyses were carried out using
Student’s t test when two groups were compared. For the compar-
ison of more than two groups, an ANOVA (one-way ANOVA) was
used, followed by the appropriate post-test (Tukey). Values were
considered significant when p < 0.05.
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